SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 78180.72
104.35 (-0.13%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
1	Health X Platform Ltd.	Q V PT	1,018 Small Cap	319.60 (-0.12%)	N/A	3.76	109.54	-201.92	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
2	Fischer Medical Ventures Ltd.	Q V PT	2,479 Small Cap	38.10 (0.61%)	N/A	7.94	96.10	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
3	3B Blackbio Dx Ltd.	Q V PT	1,034 Small Cap	1,166 (-3.25%)	20.97	3.79	46.29	132.12	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
4	Max Healthcare Institute Ltd.	Q V+ PT	1,10,230 Mid Cap	1,119.80 (-1.13%)	76.42	10.25	46.01	60.18	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
5	Indegene Ltd.	Q V+ PT	11,907 Small Cap	491.95 (-0.47%)	29.68	3.79	34.59	31.10	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
6	Acutaas Chemicals Ltd.	Q V+ PT	28,772 Small Cap	3,406 (-3.08%)	78.57	17.25	32.80	16.82	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
7	Rubicon Research Ltd.	Q V+ PT	22,539 Small Cap	1,384.50 (1.59%)	119.78	16.66	32.49	25.95	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
8	Yatharth Hospital & Trauma Care Services Ltd.	Q V PT	8,131 Small Cap	827.65 (-1.93%)	85.23	5.02	27.90	137.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
9	Dr. Agarwals Health Care Ltd.	Q V PT	15,252 Small Cap	469.90 (-2.34%)	114.51	7.53	26.38	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
10	Innova Captab Ltd.	Q V PT	5,466 Small Cap	971.60 (1.73%)	65.31	6.16	25.90	14.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
11	Sigachi Industries Ltd.	Q V+ PT	844 Small Cap	21.75 (-1.58%)	N/A	1.77	24.05	7.49	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
12	Marksans Pharma Ltd.	Q V+ PT	11,755 Small Cap	260.50 (0.42%)	39.09	7.11	22.06	32.86	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
13	Eris Lifesciences Ltd.	Q V PT	20,053 Small Cap	1,432.30 (-1.02%)	32.37	5.14	21.92	3.58	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
14	Kwality Pharmaceuticals Ltd.	Q V+ PT	2,753 Small Cap	2,548.05 (-3.96%)	40.88	8.28	21.70	37.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
15	Jupiter Life Line Hospitals Ltd.	Q V PT	9,570 Small Cap	1,464.80 (0.35%)	50.01	5.95	21.03	54.25	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
16	Poly Medicure Ltd.	Q V PT	17,094 Small Cap	1,670 (-0.98%)	50.88	5.6	19.91	26.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
17	CORONA Remedies Ltd.	Q V+ PT	12,251 Small Cap	1,980 (-1.16%)	66.28	16.42	19.49	18.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
18	KMC Speciality Hospitals (India) Ltd.	Q V PT	2,193 Small Cap	128.45 (-4.46%)	N/A	N/A	19.21	12.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
19	Concord Biotech Ltd.	Q V PT	13,433 Small Cap	1,268 (-1.25%)	51.48	6.66	18.56	18.12	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
20	Natco Pharma Ltd.	Q V PT	16,688 Small Cap	984.35 (5.65%)	11.76	1.81	18.26	32.57	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
21	Sai Life Sciences Ltd.	Q V+ PT	26,166 Small Cap	1,215.30 (-1.40%)	76.63	10.43	17.75	11.20	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
22	Dr Agarwals Eye Hospital Ltd.	Q V PT	2,419 Small Cap	5,004.05 (-0.02%)	34.51	6.98	17.68	31.54	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
23	Syncom Formulations (India) Ltd.	Q V PT	1,315 Small Cap	13.92 (-0.50%)	17.3	3.19	17.63	21.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
24	Caplin Point Laboratories Ltd.	Q V PT	19,954 Small Cap	2,566.10 (-2.25%)	31.12	5.56	17.55	21.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
25	Supriya Lifescience Ltd.	Q V+ PT	6,968 Small Cap	838.10 (-3.19%)	33.32	5.82	17.45	18.30	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
26	Global Health Ltd.	Q V PT	36,284 Small Cap	1,327 (-1.67%)	73.12	9.02	16.83	34.86	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
27	Gufic Biosciences Ltd.	Q V PT	3,761 Small Cap	379.55 (1.20%)	59.56	5.66	16.69	24.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
28	Anuh Pharma Ltd.	Q V+ PT	809 Small Cap	79.02 (-2.13%)	19.71	2.3	16.60	20.73	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
29	Windlas Biotech Ltd.	Q V PT	1,773 Small Cap	851.85 (-0.83%)	26.68	3.45	16.15	15.34	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
30	Rainbow Childrens Medicare Ltd.	Q V PT	14,640 Small Cap	1,422 (-1.35%)	58.56	8.67	15.91	24.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
IOL Chem & Pharma	164.95	14.23%
Natco Pharma	984.35	5.65%
Bliss GVS Pharma	511.55	4.69%
Akums Drugs & Pharma	650.60	4.21%
Gland Pharma	2,551	3.60%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Fermenta Biotech	368.90	-6.61%
KMC Speciality Hosp.	128.45	-4.46%
Biocon	406.90	-4.18%
Kwality Pharma	2,548.05	-3.96%
Themis Medicare	116.65	-3.60%

News about Top Pharma Companies in India

Jul, 2026

Corona Remedies informs about compliances-certificate

Pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, as amended from time to time, Corona Remedies has enclosed a copy of the certificate received from Bigshare Services, Registrar to Issue and Share Transfer Agent of the Company, for the first quarter ended on June 30, 2026.

The above information is a part of company's filings submitted to BSE.

Jul, 2026

Concord Biotech informs about newspaper publication

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Concord Biotech has enclosed copies of the newspaper advertisements published for the information of the shareholders, in compliance with the applicable provisions of the SEBI Listing Regulations and the Companies Act, 2013, read with the rules made thereunder. The advertisements contain information regarding the Company's 41st Annual General Meeting, notice of candidature for the office of Director, the record date, and the availability of the e-voting facility. Financial Express (English, All Editions); and Financial Express (Gujarati, Ahmedabad Editions).

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Supriya Lifescience informs about disclosure

Pursuant to the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other applicable laws, and in accordance with the Regulation 30 read with Para B of Part A of Schedule III of the Listing Regulations and SEBI circular dated July 13, 2023 SEBI Listing Regulations, Supriya Lifescience has informed that the investigation has been initiated yesterday against Sreekant Sreedharan, General Manager, Sales & Marketing officer of the Company by Special Investigation and Intelligence branch of Customs Department, subsequent to which judicial custody has been granted by CMM court till July 17, 2026. The Company remains committed to maintaining the highest standards of corporate governance and regulatory compliance. The Company is closely monitoring the developments in the case and any further material developments in the matter shall be disclosed to the stock exchanges in accordance with applicable laws and regulations. The details of the case as required under Circular no SEBI/HO/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 are enclosed as Annexure A to the disclosure.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

USFDA completes unannounced inspection at Rubicon Research’s Pithampur facility

Upon conclusion of the inspection, a Form 483 containing 2 observations was issued to the company

Jul, 2026

Windlas Biotech submits AGM notice

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) read with Schedule III of the said Regulations, Windlas Biotech has informed that it enclosed a copy of the Notice of the 25th Annual General Meeting (AGM) of the Company scheduled to be held on Thursday, July 23, 2026 at 01.00 PM (IST) through Video Conferencing (VC)/Other Audio ,Visual Means (OAVM), in accordance with the relevant circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India. ln compliance with the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 and Regulation 44 of the Listing Regulations, the Company is pleased to provide to its Members, facility to exercise their right to vote at the 25th AGM scheduled to be held on July 23, 2026, by electronic means and the business mentioned in the AGM Notice may be transacted through e-voting services provided by MUFG Intime India at https://instavote.linkintime.co.in/. The Company has fixed July 16, 2026 as the ‘cut-off date’ for ascertaining the names of members, holding shares of the Company, who will be entitled to cast their votes electronically during July 20, 2026 (9:00 AM) to July 22, 2026 (5:00 PM) and also during AGM in respect of business to be transacted at the aforesaid AGM and for the purpose of receiving dividend, if any.

The above information is a part of company’s filings submitted to BSE.

Jun, 2026

Concord Biotech gains on clearing PPB Kenya, NDA Uganda inspection at Unit-II formulation facility

The inspection took place from June 18, 2026 to June 24, 2026, and was concluded successfully

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Health X Platform Ltd.	1,018 Crore
2	Fischer Medical Ventures Ltd.	2,479 Crore
3	3B Blackbio Dx Ltd.	1,034 Crore
4	Max Healthcare Institute Ltd.	1,10,230 Crore
5	Indegene Ltd.	11,907 Crore
6	Acutaas Chemicals Ltd.	28,772 Crore
7	Rubicon Research Ltd.	22,539 Crore
8	Yatharth Hospital & Trauma Care Services Ltd.	8,131 Crore
9	Dr. Agarwals Health Care Ltd.	15,252 Crore
10	Innova Captab Ltd.	5,466 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	26,690	57,058	36.76	11.95	25.14	35.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,853	1,63,246	75.46	19.46	39.62	29.04
Ajanta Pharma Ltd. (M)	Very Good	3,311	42,118	39.88	9.31	26.95	25.35
Lupin Ltd. (M)	Somewhat Good	2,490	1,13,963	21.37	5.08	12.36	20.83
Zydus Lifesciences Ltd. (M)	Very Good	1,153	1,14,518	22.72	4.40	13.90	20.74

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,477	82,615	97.06
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,423	38,385	46.04
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,853	1,63,246	43.21
Aurobindo Pharma Ltd. (M)	Very Good	1,582	91,709	33.87
Gland Pharma Ltd. (S)	Very Good	2,551	40,621	31.41
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,423	38,385	56.94	9.51	34.49	15.51
Mankind Pharma Ltd. (M)	Very Good	2,530	1,04,911	51.49	6.40	32.31	14.65
Ajanta Pharma Ltd. (M)	Very Good	3,311	42,118	39.88	9.31	26.95	13.54
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,354	1,14,246	27.23	3.03	15.19	12.09
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,853	1,63,246	75.46	19.46	39.62	11.80

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Zydus Lifesciences Ltd. (M)	Very Good	1,153	1,14,518	22.72	4.40	13.90	30.57
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,903	4,59,005	39.98	5.49	22.91	23.50
Abbott India Ltd. (M)	Very Good	26,690	57,058	36.76	11.95	25.14	18.78
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,354	1,14,246	27.23	3.03	15.19	15.75
Glenmark Pharmaceuticals Ltd. (M)	Very Good	2,257	64,072	47.05	6.10	12.50	14.41

You have 9 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Corona Remedies informs about compliances-certificate

Concord Biotech informs about newspaper publication

Supriya Lifescience informs about disclosure

USFDA completes unannounced inspection at Rubicon Research’s Pithampur facility

Windlas Biotech submits AGM notice

Concord Biotech gains on clearing PPB Kenya, NDA Uganda inspection at Unit-II formulation facility

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.